证券之星消息，截至2025年9月19日收盘，春立医疗(688236)报收于22.88元，上涨0.88%，换手率 1.18%，成交量3.4万手，成交额7882.82万元。 该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为31.46。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-19 | 22.88 | 0.88% | 16.92万 | 0.21% | -20.05万 | -0.25% | 3.12万 | - 0.04% | | 2025-09-18 | 22.68 | -2.03% | -229.42万 | -5.21% | 67.17万 | 1.53% | 162.25万 | 3.69% | | 2025-09-17 | 23.15 | -1.45% | -197.25万 | -4.60% | -45.49万 | -1.06% | 242.75万 | 5.66% | | 2 ...

Core Viewpoint - The stock of Chunli Medical (688236) has experienced a decline in price and significant net outflow of funds, indicating potential investor concerns about its performance and market position [1][2]. Financial Performance - As of the latest report, Chunli Medical's total revenue for the first half of 2025 was 488 million yuan, representing a year-on-year increase of 28.27% [3]. - The net profit attributable to shareholders for the same period was 114 million yuan, up 44.85% year-on-year, while the net profit excluding non-recurring items reached 106 million yuan, marking a 61.09% increase [3]. - In Q2 2025, the company reported a single-quarter revenue of 258 million yuan, a significant year-on-year increase of 62.85%, and a net profit of approximately 56.4 million yuan, up 136.7% year-on-year [3]. Market Position and Valuation - Chunli Medical's total market capitalization is 8.699 billion yuan, which is below the industry average of 12.073 billion yuan, ranking 44 out of 123 in the medical device sector [3]. - The company's price-to-earnings (P/E) ratio is 38, compared to the industry average of 67.82, indicating a relatively lower valuation [3]. - The gross margin stands at 67.09%, significantly higher than the industry average of 51.85%, while the net margin is 23.48%, compared to the industry average of 10.39% [3]. Fund Flow Analysis - On September 18, 2025, Chunli Medical's stock price closed at 22.68 yuan, down 2.03%, with a turnover rate of 0.66% and a trading volume of 19,100 hands, resulting in a total transaction amount of approximately 43.997 million yuan [1]. - The net outflow of main funds on that day was 2.2942 million yuan, accounting for 5.21% of the total transaction amount, while retail investors saw a net inflow of 1.6225 million yuan, representing 3.69% of the total [1][2].

Core Viewpoint - Spring Medical (688236) has experienced a decline in stock price and mixed capital flow, with a notable increase in revenue and profit in its recent financial report [1][4]. Group 1: Stock Performance - As of September 15, 2025, Spring Medical's stock closed at 23.2 yuan, down 2.93% with a turnover rate of 0.84% and a trading volume of 24,200 hands, amounting to a transaction value of 56.44 million yuan [1]. - The net inflow of main funds on September 15 was 221,300 yuan, accounting for 0.39% of the total transaction value, while retail investors saw a net outflow of 674,100 yuan, representing 1.19% of the total [1]. Group 2: Financing and Margin Trading - On September 15, the financing buy amounted to 5.95 million yuan, with a net financing buy of 2.56 million yuan, while the margin trading balance stood at 35.15 million yuan [1][2]. - The financing balance on September 15 was 35.14 million yuan, reflecting a decrease in financing net buy compared to previous days [2]. Group 3: Financial Performance - For the first half of 2025, Spring Medical reported a main revenue of 488 million yuan, a year-on-year increase of 28.27%, and a net profit of 114 million yuan, up 44.85% [4]. - The company's gross profit margin was 67.09%, significantly higher than the industry average of 51.85%, indicating strong profitability [4]. Group 4: Industry Comparison - Spring Medical's total market value is 8.899 billion yuan, which is lower than the industry average of 12.186 billion yuan, ranking 44th out of 123 companies in the medical device sector [4]. - The company's price-to-earnings ratio (P/E) is 38.87, which is more favorable compared to the industry average of 69.25, ranking 45th in the industry [4].

Core Viewpoint - The stock of Chunli Medical (688236) has shown a positive performance with a closing price of 24.16 yuan, reflecting a 1.94% increase on September 11, 2025, despite some net outflows from major and retail investors [1][2]. Financial Performance - Chunli Medical reported a main revenue of 488 million yuan for the first half of 2025, representing a year-on-year increase of 28.27% [2]. - The net profit attributable to shareholders reached 114 million yuan, up 44.85% year-on-year, while the net profit after deducting non-recurring gains and losses was 106 million yuan, increasing by 61.09% [2]. - In Q2 2025, the company achieved a single-quarter main revenue of 258 million yuan, a significant rise of 62.85% year-on-year, with a net profit of approximately 56.4 million yuan, marking a 136.7% increase [2]. Market Position - Chunli Medical's total market capitalization stands at 9.267 billion yuan, which is below the industry average of 12.288 billion yuan, ranking 40th out of 123 companies in the medical device sector [2]. - The company has a price-to-earnings ratio (P/E) of 40.48, which is more favorable compared to the industry average of 67.38, ranking 47th in the industry [2]. - The gross margin of Chunli Medical is 67.09%, significantly higher than the industry average of 51.85%, ranking 27th in the sector [2]. Investor Sentiment - Over the past 90 days, four institutions have rated Chunli Medical with a "buy" recommendation, with an average target price of 28.32 yuan [3].

Core Viewpoint - The stock of Chunli Medical (688236) has shown a decline in price and mixed capital flow, with significant institutional buy ratings and strong financial performance in recent reports [1][2][3]. Group 1: Stock Performance - As of September 10, 2025, Chunli Medical's stock closed at 23.7 yuan, down 0.84%, with a turnover rate of 0.52% and a trading volume of 14,900 hands, resulting in a transaction amount of 35.17 million yuan [1]. - The net outflow of main funds on September 10 was 3.95 million yuan, accounting for 11.24% of the total transaction amount, while retail investors saw a net inflow of 2.98 million yuan, representing 8.48% of the total [1]. Group 2: Financial Performance - Chunli Medical reported a main revenue of 488 million yuan for the first half of 2025, an increase of 28.27% year-on-year, and a net profit attributable to shareholders of 114 million yuan, up 44.85% year-on-year [2]. - The company achieved a gross profit margin of 67.09% and a net profit margin of 23.48%, indicating strong profitability compared to industry averages [2]. Group 3: Industry Comparison - Chunli Medical's total market value is 9.09 billion yuan, which is below the industry average of 12.11 billion yuan, ranking 40th out of 123 companies in the medical device sector [2]. - The company's price-to-earnings ratio (P/E) stands at 39.71, significantly lower than the industry average of 66.41, ranking 46th in the industry [2]. Group 4: Analyst Ratings - In the last 90 days, four institutions have given buy ratings for Chunli Medical, with an average target price of 28.32 yuan [3].

Group 1 - The stock price of Chunli Medical (688236) closed at 23.45 yuan on September 5, 2025, with a slight increase of 0.69% and a trading volume of 25,400 hands, resulting in a transaction amount of 58.30 million yuan [1] - On September 5, 2025, the net inflow of main funds was 2.63 million yuan, accounting for 4.5% of the total transaction amount, while retail investors experienced a net outflow of 4.91 million yuan, representing 8.42% of the total transaction amount [1] - Over the past five days, the stock has seen fluctuations in fund flows, with significant net inflows and outflows from both main and retail investors [1] Group 2 - Chunli Medical's total market value is 8.995 billion yuan, with a net asset value of 2.909 billion yuan and a net profit of 114 million yuan, ranking 41st, 53rd, and 39th respectively in the medical device industry [2] - The company reported a year-on-year revenue increase of 28.27% to 488 million yuan and a net profit increase of 44.85% to 114 million yuan for the first half of 2025 [2] - In Q2 2025, Chunli Medical achieved a quarterly revenue of 258 million yuan, up 62.85% year-on-year, and a net profit of approximately 56.40 million yuan, reflecting a significant year-on-year increase of 136.7% [2] Group 3 - In the last 90 days, three institutions have rated Chunli Medical with a "buy" rating, and the average target price set by these institutions is 27.20 yuan [3] - The stock's price movements indicate a trend of fund inflow when the price is rising, and fund outflow when the price is falling, with the net effect determining the stock's price movement [3]

Core Viewpoint - The stock of Chunli Medical (688236) has experienced a decline, with a closing price of 21.92 yuan on August 27, 2025, down by 2.97% [1] Group 1: Stock Performance and Trading Data - On August 27, 2025, the stock had a turnover rate of 0.82%, with a trading volume of 23,600 lots and a transaction amount of 53.18 million yuan [1] - The net outflow of main funds was 2.87 million yuan, accounting for 5.4% of the total transaction amount, while retail investors saw a net inflow of 2.20 million yuan, representing 4.13% of the total [1][2] - Over the past five days, the stock has seen fluctuations in fund flows, with significant net inflows and outflows from different investor categories [2] Group 2: Financial Metrics and Industry Comparison - Chunli Medical's total market value is 8.408 billion yuan, which is below the industry average of 12.081 billion yuan, ranking 45th out of 123 in the medical device sector [3] - The company reported a net profit of 58.07 million yuan for the first quarter of 2025, reflecting a year-on-year increase of 5.2%, with a gross margin of 66.69% [3] - The company's price-to-earnings ratio (P/E) stands at 36.2, significantly lower than the industry average of 72.56, ranking 43rd out of 123 [3] Group 3: Analyst Ratings - In the last 90 days, two institutions have issued buy ratings for Chunli Medical, indicating positive sentiment among analysts [4]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a slight increase, with a closing price of 22.75 yuan on August 25, 2025, reflecting a 0.35% rise, while the overall market sentiment indicates mixed fund flows [1][2]. Fund Flow Summary - On August 25, 2025, the net outflow of main funds was 435.19 million yuan, accounting for 7.46% of the total transaction amount, while retail investors saw a net inflow of 481.9 million yuan, representing 8.27% of the total [1][2]. - Over the past five days, the fund flow data shows fluctuations, with significant net outflows from main funds on August 22 (2008.72 million yuan) and August 21 (252.93 million yuan), while retail investors had notable inflows on those days [2]. Company Performance Metrics - Chunli Medical's total market value is 8.726 billion yuan, with a net asset value of 2.879 billion yuan and a net profit of 58.071 million yuan, ranking 45th, 52nd, and 42nd respectively in the medical device industry [3]. - The company reported a gross margin of 66.69% and a net margin of 25.25%, both of which are significantly higher than the industry averages of 51.33% and 10.71% respectively [3]. - In the first quarter of 2025, the company's main revenue was 230 million yuan, showing a year-on-year increase of 3.6%, while the net profit increased by 5.2% [3]. Industry Ratings - In the last 90 days, three institutions have issued buy ratings for Chunli Medical, indicating positive sentiment towards the stock [4].

Core Viewpoint - The stock of Chunli Medical (688236) has shown a slight increase, with a closing price of 23.29 yuan on August 20, 2025, reflecting a 1.57% rise, amidst mixed capital flows from different investor categories [1][2]. Group 1: Stock Performance and Capital Flow - On August 20, 2025, Chunli Medical's stock recorded a trading volume of 33,100 hands and a total transaction amount of 76.81 million yuan [1]. - The net inflow of main funds was 2.3652 million yuan, accounting for 3.08% of the total transaction amount, while retail investors experienced a net outflow of 3.998 million yuan, representing 5.20% of the total [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with the highest net inflow of main funds recorded on August 19 at 2.5814 million yuan, and the largest net outflow of retail funds on August 14 at 7.4103 million yuan [2]. Group 2: Financial Metrics and Industry Comparison - Chunli Medical's total market value is 8.933 billion yuan, which is below the industry average of 12.109 billion yuan, ranking 43rd out of 123 companies in the medical device sector [3]. - The company reported a net profit of 58.0711 million yuan for Q1 2025, reflecting a year-on-year increase of 5.2%, with a gross margin of 66.69%, significantly higher than the industry average of 51.29% [3]. - The company's return on equity (ROE) stands at 2.04%, outperforming the industry average of 1.28%, indicating a relatively efficient use of equity capital [3]. Group 3: Analyst Ratings - In the last 90 days, three institutions have provided ratings for Chunli Medical, all of which are buy ratings, indicating a positive outlook from analysts [4].

Core Viewpoint - The stock of Chunli Medical (688236) has shown a recent increase in price and fluctuating capital flows, indicating mixed investor sentiment and potential opportunities for further analysis [1][2]. Group 1: Stock Performance - As of August 15, 2025, Chunli Medical's stock closed at 23.77 yuan, up by 1.89% with a turnover rate of 0.97% and a trading volume of 28,000 hands, resulting in a transaction amount of 65.80 million yuan [1]. - The capital flow data on August 15 shows a net inflow of 388,900 yuan from institutional investors, accounting for 0.59% of the total transaction amount, while retail investors experienced a net outflow of 2.62 million yuan, representing 3.98% of the total [1][2]. Group 2: Recent Capital Flows - Over the past five days, the stock has experienced varying capital flows, with notable net inflows and outflows from different investor categories [2]. - On August 14, the stock saw a significant net outflow of 7.41 million yuan from institutional investors, while retail investors had a net inflow of 3.25 million yuan [2]. Group 3: Financial Metrics and Industry Comparison - Chunli Medical's total market capitalization is 9.117 billion yuan, with a net asset value of 2.879 billion yuan and a net profit of 58.07 million yuan, ranking 42nd, 52nd, and 38th respectively in the medical device industry [3]. - The company reported a gross margin of 66.69% and a net margin of 25.25%, both significantly higher than the industry averages of 51.36% and 10.89% respectively [3]. - Chunli Medical's price-to-earnings ratio is 39.25, which is lower than the industry average of 67.67, indicating a potentially undervalued position in the market [3]. Group 4: Analyst Ratings - In the last 90 days, four institutions have provided ratings for Chunli Medical, with three giving a "buy" rating and one an "accumulate" rating, suggesting a generally positive outlook among analysts [4].